Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended budesonide enteric capsule treatment in primary IgA nephropathy
ChiCTR2600131870Phase 4Not yet recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide in IgA nephropathy (IgAN), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoint: Change in proteinuria levels from baseline at 9 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2600131870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131870.